Why Does Mental Health Awareness Month Create Claim Risk for Digital Health Founders?

When every company in the space amplifies mental health messaging at the same time, the pressure to stand out increases. And when every company is making the same sweeping claims at the same time, the space doesn’t just feel louder, it feels saturated, which makes precision the only real differentiator.

A pilot showed improvement. Early users gave strong feedback. Engagement exceeded expectations. These are legitimate signals. They are not clinical validation, and how they’re communicated matters more than most founders realize.

The FTC and FDA both regulate health-related marketing claims. The line between a “wellness claim” and a “disease claim” is less obvious than it looks. When messaging drifts from “supports stress management” toward “reduces anxiety” or “treats depression,” the regulatory landscape shifts in ways that create real downstream risk.

Awareness months compress timelines and amplify the impulse to stretch beyond what the evidence actually supports. Claim discipline is how founders protect themselves before and after May.

What Are the Riskiest Claim Patterns in Mental Health Marketing?

Most overreaching isn’t intentional. It comes from language that sounds reasonable but implies more than the evidence can back up.

Causal claims without causal evidence. 
Saying a product “reduces anxiety” or “improves depression symptoms” implies a direct, tested causal relationship. Unless controlled study data supports that specific outcome, the evidence can’t carry it. User surveys and self-reported satisfaction are meaningful signals. They don’t establish causality.

Population-level statements from small pilots. 
“Users experience significant improvement in stress levels” may be accurate within a pilot cohort but misleading when presented as a general product claim. Sample size, study design, and the specific population studied all matter when a statement implies broad effectiveness.

Outcome language attached to engagement data. 
Engagement and outcomes are not interchangeable. Research shows the median 30-day retention rate for mental health apps in real-world settings is approximately 3.3%, meaning active users are unlikely to represent the full user base. Building a benefit claim on data from the most engaged users creates a distorted picture. Sophisticated investors and enterprise buyers will catch it.

Borrowed research as product proof. 
Citing peer-reviewed literature on mindfulness or CBT to support a product’s effectiveness is common. It is not the same as having evidence that the specific product you built works. The underlying science can be valid while the product itself is unvalidated. These are different claims, and conflating them is a credibility risk.

What Is the Difference Between User-Reported Value, Engagement, and Clinical Outcomes?

This is the distinction that matters most for getting claims right.

User-reported value is what users say about their experience: satisfaction data, qualitative feedback, testimonials. It signals that people find the product useful. It’s meaningful. It’s also subjective, and it isn’t a substitute for measured outcomes.

Engagement is observable. Did users complete sessions consistently? Did they return without prompting? This data is more objective, but it tells you what people did, not whether it helped them.

Clinical outcomes are measured changes in validated health indicators: symptom reduction on a validated scale, change in a clinical variable with established meaning in the research literature. This is the standard regulators, payers, and health systems use to evaluate digital health tools.

Most early-stage mental health products have evidence at the first level, sometimes the second, and rarely the third. That’s appropriate for the stage. The mistake is reaching for clinical outcome language when the evidence is at the user-reported level.

Here’s the practical version: “Our users report feeling less stressed after using the app” is defensible if that’s what users said. “Our app reduces stress” is not. The difference between those two sentences is the difference between a credible claim and an exposed one.

How Should Founders Market a Mental Health Product When the Evidence Is Still Emerging?

The answer isn’t to go quiet. It’s to get precise.

Lead with what was observed, not what was concluded. 
“In our pilot, 78% of participants reported improved sleep quality after 30 days” is accurate and compelling. “Our product improves sleep quality” overreaches unless the study design supports a causal conclusion. One is a finding. The other is a product claim. Know the difference before publishing either.

Be specific about who was studied.
Evidence from a defined population is more credible than evidence claimed to generalize broadly. Naming the cohort signals scientific literacy and builds trust with the investors, partners, and enterprise buyers who know the difference.

Name what hasn’t been tested yet. 
This one feels counterintuitive, but acknowledging the limits of current evidence is often what separates a founder who understands their data from one who doesn’t. “We’re building toward a rigorous outcome study; here’s what we know right now” is a more fundable position than certainty that hasn’t been earned.

Separate user stories from product claims. 
Testimonials communicate real-world value without requiring population-level efficacy claims. Use them. Just don’t let them carry the weight of clinical evidence in investor or enterprise conversations.

Why Precise Claims Build More Credibility Than Broad Ones

There’s a commercial reason precision matters, not just a credibility one.

Broad claims create surface-level exposure most founders don’t notice until it’s too late. The wrong language on a website can trigger FTC scrutiny. Overstated efficacy in a pitch deck can create liability in due diligence. And the bigger the claim relative to the evidence, the harder it becomes to defend in the rooms where it counts most: enterprise sales, payer conversations, and health system partnerships.

Precise claims do the opposite. They signal that the team understands the limits of their evidence, which is exactly what sophisticated buyers want to see. A founder who says “in our 12-week pilot with 120 participants, we observed a statistically significant reduction in GAD-7 scores, and we’re designing a follow-on study to test generalizability” isn’t hedging. They’re demonstrating scientific fluency. That’s what earns trust in conversations where trust is the deciding variable.

Mental Health Awareness Month is a real opportunity. Founders who use it to sharpen their claim discipline, not stretch beyond what their evidence supports, come out of May with their credibility intact and their risk exposure lower.

Building a science strategy that supports responsible, credible marketing is exactly what the Science Strategy for Early-Stage Founders masterclass was designed for. In honor of Mental Health Awareness Month, it’s 25% off with code HEALTH26.

FAQ

What’s the difference between a wellness claim and a clinical claim?

Wellness claims generally describe support for overall well-being, lifestyle, or healthy habits, such as “supports relaxation” or “helps users build mindfulness routines.” Clinical claims imply a product can diagnose, treat, prevent, or reduce symptoms of a medical or mental health condition, such as anxiety or depression. The distinction matters because clinical claims carry a higher regulatory and evidence burden.

Can digital health companies use testimonials as evidence?

Testimonials can support marketing by illustrating user experience and perceived value, but they are not the same as clinical evidence. Founders should avoid presenting testimonials as proof of efficacy or generalizable outcomes, especially when making health-related claims. The strongest approach is to clearly separate anecdotal experience from validated product evidence.

What kind of evidence do early-stage mental health startups actually need?

Most early-stage companies do not need randomized controlled trials immediately. At this stage, investors, partners, and buyers are often looking for evidence that the team understands the target population, has identified meaningful user needs, and can demonstrate early signals of usability, engagement, or perceived value. The key is matching the level of evidence to the company’s stage and the claims being made.